Guava Technologies said last week that it has promoted Lawrence Bruder to the position of CEO (see story, this issue).
Bruder served as Guava's chief operating officer and president since July, when he was promoted to the position. Prior to that, he served as vice president of corporate development and worldwide marketing. He has held vice-president-level positions at Applied Biosystems and Becton Dickinson, and has held various marketing, sales, and product management positions with Leica and Olympus. He holds a master of management degree from Kellogg Management School at Northwestern University, and a BS from Rochester Institute of Technology.
Guava also hired Todd Christian as vice president, commercial operations, and Lalit Dhir as vice president of corporate development and strategic marketing.
Christian previously was served various roles in product development, program management, and global marketing across multiple business units at Applied Biosystems, and served as general manager of ABI's cell biology incubator. Prior to this, he was a general manager for BD Biosciences' Canadian operations. He also has served as director or program management, product development, custom products, and marketing with BD Biosciences. He holds a BA in biology from Hamilton College.
Dhir joined Guava from BD Biosciences, where he led strategy planning and corporate development. He also served as manager of business development at BD's Pharmingen division. He holds an MBA from San Diego State University, and an MS and BS in biochemistry from Panjab University in India.
Trevor Bell, Genetix Group's current chief operating officer, will be resigning from the Board of Directors on Jan. 11, 2006, the company said last week.
According to Genetix, the departure follows changes to the board that will make the role of a chief operating officer redundant.
ForteBio announced last week the introduction of its first product — the Octet System for label-free, real-time detection and analysis of molecular interactions.
The Octet System is based on a proprietary technique called BioLayer Interferometry. It incorporates a sensitive optical detector and a series of application-specific biosensor consumables. According to ForteBio, the biosensors provide a way to make critical measurements even in crude samples, at early stages in antibody development.